<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Skin picking (excoriation) disorder and related disorders</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Skin picking (excoriation) disorder and related disorders</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Skin picking (excoriation) disorder and related disorders</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kelly KyungHwa Park, MD, MSL</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Koo, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Erik Stratman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15211814"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Skin picking disorder (SPD) is characterized by deliberate and repetitive manipulation of the skin, causing tissue damage. Excoriation disorder, psychogenic excoriation, neurodermatitis, neurotic excoriation, acne excoriée, and dermatillomania (dermatotillomania) are in the spectrum of SPD and may be considered synonyms.</p><p>This topic will discuss the clinical manifestations, diagnosis, and treatment of SPD and related conditions. Obsessive-compulsive disorder and body dysmorphic disorder are discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/498.html" rel="external">"Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/86436.html" rel="external">"Obsessive-compulsive disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14825.html" rel="external">"Body dysmorphic disorder: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/96883.html" rel="external">"Body dysmorphic disorder: Assessment, diagnosis, and differential diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H44169844"><span class="h1">DEFINITION AND CLASSIFICATION</span><span class="headingEndMark"> — </span>SPD is defined as the repetitive picking, scratching, rubbing, digging, or squeezing of skin, resulting in visible tissue damage and impairment in social functioning [<a href="#rid1">1</a>]. In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), SPD is included as a separate diagnosis in the group of the obsessive-compulsive and related disorders, along with trichotillomania and body dysmorphic disorder [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H15211823"><span class="h1">EPIDEMIOLOGY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevalence</strong> – The exact prevalence of SPD in the general population is unknown. In a survey of over 10,000 participants aged 18 to 69 years representative of the United States population, the prevalence of SPD was 2 percent [<a href="#rid3">3</a>]. SPD accounts for approximately 2 percent of all visits to the dermatology clinic [<a href="#rid4">4,5</a>]. In a telephone survey, 1.6 percent of a random sample of 2511 adults residing in the United States reported skin picking with noticeable skin damage [<a href="#rid6">6</a>]. These individuals also reported distress and psychosocial impact associated with skin picking. In another United States population-based study, 5.4 percent of 354 participants reported SPD and associated impairment in daily functioning [<a href="#rid7">7</a>]. In a web-based, anonymous survey including over 7600 participants, the prevalence of SPD was 3.4 percent (95% CI 3.0-3.8 percent) [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1">In three samples of college students, the rates of severe, self-injurious skin picking ranged from 3.8 to 4.6 percent [<a href="#rid9">9-11</a>]. SPD was associated with high lifetime rates of affective disorders, anxiety disorders, eating disorders, substance abuse, and impulse control disorders and was usually triggered by cutaneous stimuli or specific emotional situations. In a large sample of over 4000 college students, nearly 60 percent of participants reported engaging occasionally in body-focused repetitive behaviors (BFRBs), including skin picking, hair pulling, and nail biting, while 12 percent met the criteria for pathologic BFRB [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex predominance</strong> – SPD is most common in females, with a female-to-male ratio of approximately 8:1 [<a href="#rid6">6-8,13-15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Age of onset</strong> – The age of onset of SPD spans between 15 and 45 years, with a peak noted in the early twenties [<a href="#rid10">10</a>]. In a study of 700 patients with SPD, latent profile analysis identified a large group (93 percent) with onset in adolescence at a mean age of 14 years and a small group (7 percent) with onset in middle adulthood (mean age 43 years) [<a href="#rid16">16</a>]. The duration of illness ranges from 5 to 21 years [<a href="#rid9">9,10</a>]. Childhood onset may progress into adulthood in up to 47 percent of cases [<a href="#rid10">10</a>]. Individuals with childhood-onset disease share similar characteristics with those with late-onset disease [<a href="#rid1">1</a>]. However, childhood onset is associated with longer disease duration and less motivation for treatment [<a href="#rid17">17</a>].</p><p></p><p class="headingAnchor" id="H23073601"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The pathogenesis of SPD is unknown. Research is focused on identifying the neural circuitry involved in the pathophysiology of SPD and other obsessive-compulsive disorders by using neuroimaging techniques. A functional magnetic resonance imaging (fMRI) study found abnormal activation of brain areas involved in habit formation, action monitoring, and inhibition [<a href="#rid18">18</a>]. Another study using diffuser tensor imaging found that SPD was associated with bilateral disorganization or damage of white matter tracts in the anterior cingulate cortex [<a href="#rid19">19</a>]. Another fMRI study found that SPD patients had decreased gray matter volumes in left cerebellar lobules V (motor) and VI (affective-cognitive) compared with controls. This may indicate a structural pathogenesis in SPD. When performing picking activities, affected patients had more activation of the left crus I and enhanced coupling with the left ventrolateral prefrontal cortex. This may suggest that SPD is a maladaptive response to an emotional trigger [<a href="#rid20">20</a>]. fMRI with visual symptom provocation found higher activity levels in the insula and amygdala, which correlated with emotional distress (ie, disgust and self-loathing) [<a href="#rid21">21</a>]. Furthermore, there appears to be differences in the insular cortex and parietal and occipital regions associated with motor impulsivity in SPD [<a href="#rid22">22</a>].</p><p class="headingAnchor" id="H15211830"><span class="h1">COMORBID CONDITIONS</span><span class="headingEndMark"> — </span>Multiple psychiatric comorbidities are associated with SPD. These include major psychiatric disorders as well as related disorders, such as trichotillomania and onychophagia. In several studies, the following conditions were associated with SPD, with higher prevalences reported among patients attending psychiatric outpatient facilities [<a href="#rid8">8,13,23-26</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Depression</p><p class="bulletIndent1"><span class="glyph">●</span>Bipolar disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Obsessive-compulsive disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Alcohol abuse/dependence</p><p class="bulletIndent1"><span class="glyph">●</span>Substance abuse/dependence</p><p class="bulletIndent1"><span class="glyph">●</span>Body dysmorphic disorder</p><p class="bulletIndent1"><span class="glyph">●</span>Trichotillomania</p><p class="bulletIndent1"><span class="glyph">●</span>Onychophagia</p><p class="bulletIndent1"><span class="glyph">●</span>Kleptomania</p><p class="bulletIndent1"><span class="glyph">●</span>Bulimia nervosa</p><p></p><p>Skin picking is a characteristic common feature of Prader-Willi syndrome, a complex neurodevelopmental disorder caused by an abnormality on the long arm of chromosome 15 (q11-q13) and characterized by obesity, excessive interest in food, skin picking, and obsessive and compulsive behaviors. (See  <a class="medical medical_review" href="/d/html/5864.html" rel="external">"Prader-Willi syndrome: Management"</a>.)</p><p>Self-mutilation and skin picking can also be seen in patients with Lesch-Nyhan syndrome, autistic spectrum disorders, schizophrenia, intellectual disability and developmental delay, Smith-Magenis syndrome, Tourette syndrome, and chronic tic disorders. (See  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a> and  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'</a> and  <a class="medical medical_review" href="/d/html/6221.html" rel="external">"Tourette syndrome: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H15211837"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>SPD appears as excoriated, polymorphic lesions of varying size, with wide variation in extent and severity. All stages of evolution may be represented on a background of postinflammatory hypo- or hyperpigmentation [<a href="#rid27">27-29</a>]. Recently induced lesions appear as angular excoriations with a serosanguineous crust; older lesions may be crusted or appear as hypertrophic nodules or atrophic scars. The appearance also depends on the specific method of SPD. Instrumentation may be employed by the use of fingers or fingernails, teeth, scissors, tweezers, or pins, producing deeper lesions that extend into the dermis [<a href="#rid10">10</a>]. Complications of SPD include ulceration, infection, scarring, and disfigurement. Severe medical complications have also been reported [<a href="#rid14">14</a>].</p><p>Frequently targeted sites are the face (in particular the nose, forehead, cheeks, and chin), the scalp, cuticles, extensor aspects of the extremities, shoulders, back, perianal region, and the scrotal area [<a href="#rid10">10</a>]. Lesions are usually symmetrically distributed within reach of the hands  (<a class="graphic graphic_picture graphicRef60854 graphicRef72635 graphicRef53693 graphicRef61686 graphicRef66802 graphicRef55043 graphicRef82620" href="/d/graphic/60854.html" rel="external">picture 1A-G</a>).</p><p>Patients with SPD will usually acknowledge an urge to pick and gouge at their skin. Although there may be an initial reluctance to disclose self-damage, patients are generally willing to discuss the need to pick as a response to itch to relieve tension.</p><p>Patients may begin with the urge to manipulate a trivial skin lesion, such as an arthropod bite, acne lesion, scab, inflammatory lesion, wart, mole, or keratin plug [<a href="#rid10">10,29-31</a>]. Others may manipulate perfectly normal skin or pick the skin as a response to a cutaneous sensation of pruritus, burning, or pain [<a href="#rid32">32</a>].</p><p>An SPD episode typically lasts 6 to 10 minutes; however, it is not uncommon for patients to dedicate hours to the process on a daily basis [<a href="#rid10">10,23</a>]. Activity peaks in the evening between the hours of 8:00 PM and 12:00 AM [<a href="#rid9">9,10</a>]. Situations correlated with SPD activity include looking in a mirror, speaking on the telephone, lying in bed, reading, watching television, waiting, and bathing [<a href="#rid10">10</a>].</p><p>Patients may give various explanations for their SPD. They may report anxiety or emotional distress until they are able to pick their skin, which relieves these feelings [<a href="#rid10">10,33</a>]. There are also a proportion of patients who report an attempt to improve the appearance of their skin, those that report that it is simply a common habit, and others who find the actions pleasurable [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H44169867"><span class="h1">PATIENT EVALUATION AND DIAGNOSIS</span></p><p class="headingAnchor" id="H11728278"><span class="h2">Clinical interview</span><span class="headingEndMark"> — </span>Medical, psychiatric, and skin picking-related history should be elicited from patients with SPD [<a href="#rid34">34</a>]. Taking ample time to interview the patient is useful to assess the individual's current clinical manifestations, the associated impairment and distress, and any underlying psychiatric disorder(s) [<a href="#rid34">34</a>].</p><p>Some patients may spontaneously report a concomitant psychiatric illness at presentation. Others may be reluctant to reveal their diagnosis or do not have a previous diagnosis. In these cases, psychiatric referral should be strongly considered, although many patients will not readily accept referral.</p><p class="headingAnchor" id="H1262257070"><span class="h2">Physical examination</span><span class="headingEndMark"> — </span>Physical examination should include a thorough dermatologic evaluation to assess the severity of excoriation, the presence of complications (scarring, infections), or coexistent primary skin disorders associated with chronic pruritus, including atopic dermatitis, psoriasis, scabies, prurigo nodularis, or bullous pemphigoid. (See <a class="local">'Differential diagnosis'</a> below and <a class="local">'Primary skin disorders'</a> below.)</p><p>If a medical or organic cause is suspected to be the underlying etiology of chronic pruritus and skin picking, appropriate work-up should be instituted to rule out organ dysfunction, nutritional deficiencies, or malignancies. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p class="headingAnchor" id="H3681685421"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for SPD are as follows [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent skin picking resulting in skin lesions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeated attempts to decrease or stop skin picking.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The skin picking causes clinically significant distress or impairment in social, occupational, or other important areas of functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The skin picking is not attributable to the physiologic effect of a substance (eg, cocaine) or another medical condition (eg, scabies).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The skin picking is not better explained by symptoms of another mental disorder (eg, delusions or tactile hallucinations in a psychotic disorder, attempts to improve a perceived defect or flaw in appearance in body dysmorphic disorder, stereotypes in stereotypic movement disorder, or intention to harm oneself in nonsuicidal self-injury).</p><p></p><p class="headingAnchor" id="H2914885270"><span class="h2">Severity assessment tools</span><span class="headingEndMark"> — </span>Disease severity and behavioral styles can be assessed by using several validated instruments, including:</p><p class="bulletIndent1"><span class="glyph">●</span>Skin Picking Severity Scale (SPS) [<a href="#rid35">35,36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Skin Picking Severity Scale-Revised (SPS-R) [<a href="#rid36">36</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Milwaukee Inventory for the Dimensions of Adult Skin Picking (MIDAS) [<a href="#rid37">37</a>]</p><p></p><p class="headingAnchor" id="H572775"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>SPD should be differentiated from excoriations seen in patients with primary pruritic skin disorders or in patients with systemic conditions associated with chronic pruritus. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p>Other psychocutaneous syndromes associated with self-injurious behavior, including dermatitis artefacta, delusional infestation (also called delusional parasitosis), and body dysmorphic disorder, should be differentiated from primary SPD. (See  <a class="medical medical_review" href="/d/html/6957.html" rel="external">"Delusional infestation: Epidemiology, clinical presentation, assessment, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/14825.html" rel="external">"Body dysmorphic disorder: Clinical features"</a>.)</p><p class="headingAnchor" id="H18457059"><span class="h2">Primary skin disorders</span><span class="headingEndMark"> — </span>Patients with pruritic skin diseases may present with psychiatric disorders, most often depression or anxiety disorders, which are secondary to the skin disease. Preoccupation with poor quality of life, decreased self-esteem and self-confidence, experience of rejection, and feelings of shame or guilt may be present in patients with chronic skin conditions [<a href="#rid9">9,38</a>]. The skin disease may affect interpersonal relationships and interactions and lead to social avoidance [<a href="#rid9">9,38</a>]. In addition, the itch-scratch cycle in these patients can be triggered or exacerbated by stressors, such as psychologic stress or environmental changes [<a href="#rid39">39</a>].</p><p>Primary pruritic dermatoses include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atopic dermatitis </strong>–<strong> </strong>Atopic dermatitis is characterized by thickened skin, increased skin markings (lichenification), and excoriated and fibrotic papules  (<a class="graphic graphic_picture graphicRef64525 graphicRef55375" href="/d/graphic/64525.html" rel="external">picture 2A-B</a>). The diagnosis of atopic dermatitis is supported by a history or visible evidence of itchy dermatitis involving the flexural surfaces  (<a class="graphic graphic_picture graphicRef57982" href="/d/graphic/57982.html" rel="external">picture 3</a>), a history of symptoms beginning in infancy or childhood, and the presence of generally dry skin within the past year. (See  <a class="medical medical_review" href="/d/html/1729.html" rel="external">"Atopic dermatitis (eczema): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psoriasis </strong>–<strong> </strong>Psoriasis is often associated with pruritus. It is not restricted to the area of the psoriatic plaque, often being generalized and poorly responsive to antipruritics. (See  <a class="medical medical_review" href="/d/html/5664.html" rel="external">"Psoriasis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Scabies </strong>–<strong> </strong>Scabies is caused by the mite <em>Sarcoptes scabiei</em>, which lays its eggs in the epidermal layer of human skin. The outstanding clinical feature of scabies is intense itching. It is often severe and usually worse in the evening and night. Lesions may appear as small, erythematous papules or nodules, often excoriated with hemorrhagic crust  (<a class="graphic graphic_picture graphicRef75169" href="/d/graphic/75169.html" rel="external">picture 4</a>). (See  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/d/html/4038.html" rel="external">"Scabies: Epidemiology, clinical features, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bullous pemphigoid </strong>–<strong> </strong>Bullous pemphigoid is an autoimmune subepidermal blistering disease occurring most frequently in older adult individuals. Bullous pemphigoid may present in a subgroup of patients with pruritus and an eruption similar to prurigo nodularis (pemphigoid nodularis)  (<a class="graphic graphic_picture graphicRef69828" href="/d/graphic/69828.html" rel="external">picture 5</a>) [<a href="#rid40">40</a>]. A skin biopsy for histologic examination and direct immunofluorescence and the measurement of circulating autoantibodies against bullous pemphigoid antigens confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/16176.html" rel="external">"Clinical features and diagnosis of bullous pemphigoid and mucous membrane pemphigoid"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Trigeminal trophic syndrome</strong> – Trigeminal trophic syndrome happens as the result of trigeminal nerve or sensory nuclei damage. Altered sensation, most commonly around the nose and nasal alar areas, leads to repetitive, self-induced trauma causing ulceration and disfigurement  (<a class="graphic graphic_picture graphicRef122796" href="/d/graphic/122796.html" rel="external">picture 6</a>). It less commonly affects other areas on the head or neck. (See  <a class="medical medical_review" href="/d/html/3355.html" rel="external">"Overview of craniofacial pain", section on 'Trigeminal trophic syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prurigo nodularis/chronic prurigo</strong> – Prurigo nodularis is a chronic skin disorder of unclear pathogenesis characterized by multiple firm, itchy nodules typically localized to the extensor surface of the extremities  (<a class="graphic graphic_picture graphicRef53475 graphicRef66268" href="/d/graphic/53475.html" rel="external">picture 7A-B</a>) [<a href="#rid41">41</a>]. Pruritus is always severe and distressing. Underlying causes of chronic pruritus and repetitive scratching may include atopic dermatitis (in nearly half of the patients), other dermatologic conditions, systemic disease, emotional stress, or psychiatric disorder (eg, anxiety, depression). (See  <a class="medical medical_review" href="/d/html/13667.html" rel="external">"Prurigo nodularis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Midface toddler excoriation syndrome</strong> – Midface toddler excoriation syndrome (MiTES) is a rare disorder caused by congenital insensitivity to pain presenting in young children with self-inflicted, severe, midfacial excoriations and scarring [<a href="#rid42">42-44</a>]. MiTES is associated with biallelic mutations in <em>PRDM12</em>, encoding a member of a family of transcriptional regulators involved in the development of sensory neurons into nociceptors [<a href="#rid42">42</a>].</p><p></p><p class="headingAnchor" id="H18457251"><span class="h2">Systemic diseases associated with chronic pruritus</span><span class="headingEndMark"> — </span>Several systemic conditions may be associated with intense and persistent pruritus in the absence of primary skin disease [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Systemic disorders'</a>.)</p><p>Secondary skin changes, including nodular lesions similar to prurigo nodularis, eczematization, excoriation, and lichenification, can be observed in patients with:</p><p class="bulletIndent1"><span class="glyph">●</span>Uremia</p><p class="bulletIndent1"><span class="glyph">●</span>Cholestasis and primary biliary cholangitis</p><p class="bulletIndent1"><span class="glyph">●</span>Polycythemia vera</p><p class="bulletIndent1"><span class="glyph">●</span>Lymphoma</p><p class="bulletIndent1"><span class="glyph">●</span>Solid organ tumors</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism</p><p class="bulletIndent1"><span class="glyph">●</span>Iron deficiency</p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection</p><p class="bulletIndent1"><span class="glyph">●</span>Advanced age</p><p class="bulletIndent1"><span class="glyph">●</span>Drug or alcohol dependence/abuse</p><p></p><p class="headingAnchor" id="H18457259"><span class="h2">Other psychocutaneous syndromes</span><span class="headingEndMark"> — </span>Other psychocutaneous syndromes that should be differentiated from SPD include dermatitis artefacta, delusional infestation, and body dysmorphic disorders [<a href="#rid46">46</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dermatitis artefacta</strong> – Dermatitis artefacta is a psychocutaneous disorder in which patients intentionally induce skin lesions in order to simulate disease and assume the patient role [<a href="#rid47">47,48</a>]. The lesions of dermatitis artefacta usually appear at an identical stage of development; can be single or multiple; are often geometric, unilateral, or bilateral; and are generally within reach of the hands  (<a class="graphic graphic_picture graphicRef76670 graphicRef55697 graphicRef67422" href="/d/graphic/76670.html" rel="external">picture 8A-C</a>). The lesions can be created by the use of sharp instruments or by applying or injecting chemical substances into the skin. Characteristically, patients describe the sudden appearance of complete lesions, with little or no prodrome ("hollow history"), and usually deny taking part in the process, exhibiting a "belle indifference" and lack of frustration despite the recurrent nature of their symptomatology [<a href="#rid49">49,50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delusional infestation</strong> – Delusional infestation is a rare disorder in which affected individuals have the fixed, false belief (delusion) that their skin is infested by parasites. No obvious skin disease may be present, but excoriations frequently result from the patient's attempt to extract the imaginary parasites. Patients often bring in specimens that they have picked from their skin for examination; these may include scales, scabs, or cloth fibers but do not include parasites. (See  <a class="medical medical_review" href="/d/html/6957.html" rel="external">"Delusional infestation: Epidemiology, clinical presentation, assessment, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Body dysmorphic disorder</strong> – Body dysmorphic disorder, or dysmorphophobia, is a disturbance of the body image manifesting as a preoccupation with an imagined or exaggerated defect in physical appearance. Skin picking is common among patients with body dysmorphic disorder. Approximately one-third of patients compulsively pick at their skin, trying to remove minor blemishes or otherwise clear or perfect their skin [<a href="#rid51">51</a>]. Patients often report multiple dermatologic consultations and express dissatisfaction with previous treatments. (See  <a class="medical medical_review" href="/d/html/14825.html" rel="external">"Body dysmorphic disorder: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factitious disorder (Munchausen syndrome) </strong>– Factitious disorder, which was previously known as Munchausen syndrome, is the falsification of disease even without an obvious reward. This can manifest in cutaneous symptoms. This is different from factitious disorder imposed on another (most commonly a child). (See  <a class="medical medical_review" href="/d/html/7765.html" rel="external">"Factitious disorder imposed on self (Munchausen syndrome)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Malingering </strong>– Malingering involves the falsification of illness in order to gain an external reward. (See  <a class="medical medical_review" href="/d/html/7765.html" rel="external">"Factitious disorder imposed on self (Munchausen syndrome)", section on 'Malingering'</a>.)</p><p></p><p class="headingAnchor" id="H58784921"><span class="h1">MANAGEMENT</span></p><p class="headingAnchor" id="H15211851"><span class="h2">General considerations</span><span class="headingEndMark"> — </span>The management of SPD is notoriously difficult [<a href="#rid52">52</a>]. Treatment involves three elements [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Optimization of the patient's mental state in terms of insight, motivation, and awareness</p><p class="bulletIndent1"><span class="glyph">●</span>Pharmacologic therapies</p><p class="bulletIndent1"><span class="glyph">●</span>Nonpharmacologic therapies</p><p></p><p>Patients with SPD should be managed by clinicians who have expertise in the use of psychotropic medications as well as topical medications. This may require a multidisciplinary approach with psychiatry and dermatology or management by a specialist who has experience in both psychiatric and dermatologic disorders. </p><p>The treatment plan should be based upon a thorough discussion with the patient and should include close monitoring for both clinical efficacy and adverse effects. Standardized assessment tools for disease severity may be helpful to assess SPD severity at the beginning of treatment and monitor treatment effects over time. (See <a class="local">'Severity assessment tools'</a> above.) </p><p class="headingAnchor" id="H7747779"><span class="h2">Treatment of skin lesions</span><span class="headingEndMark"> — </span>Complications of SPD, including skin infection or disfigurement, may require medical, surgical, or cosmetic intervention. Topical and/or systemic antibiotics may be prescribed to treat secondarily infected excoriations or ulcerations. Semiocclusive dressings may be useful to limit further skin damage and promote healing. </p><p>In patients with SPD and associated pruritus, potent topical corticosteroids (groups 1 to 3  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>)) or intralesional glucocorticoids, such as <a class="drug drug_general" data-topicid="10015" href="/d/drug information/10015.html" rel="external">triamcinolone</a> acetonide, are commonly used and appear to provide benefit. However, there are no published studies of efficacy of topical or intralesional corticosteroids for SPD, and their use is mainly based on clinical experience. We typically initiate therapy with a high-potency corticosteroid for nonfacial lesions and taper the potency of the topical steroid as response is observed. </p><p>Phototherapy with narrowband ultraviolet B (UVB) has been reported as beneficial in reducing pruritus and skin picking behaviors in a small series of patients [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.) </p><p>For patients with acne excoriée, appropriate treatment of the underlying acne should be initiated, depending on acne severity and type. Laser treatment for scars has been used in case reports [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/42.html" rel="external">"Acne vulgaris: Overview of management"</a> and  <a class="medical medical_review" href="/d/html/90260.html" rel="external">"Management of acne scars"</a>.)</p><p class="headingAnchor" id="H3186851464"><span class="h2">Behavioral therapies</span><span class="headingEndMark"> — </span>Cognitive-behavioral therapies may be beneficial for patients accepting psychiatric referral. Data from observational studies and a few randomized trials examining nonpharmacologic therapeutic options for SPD, including cognitive-behavioral therapy, habit reversal therapy, and acceptance-enhanced behavior/acceptance and commitment therapy, have shown improvement of SPD with the interventions [<a href="#rid52">52,56-59</a>]. Preliminary data on clinician-guided self-help therapy using internet-based programs for SPD have shown promising results [<a href="#rid60">60</a>] (see  <a class="medical medical_review" href="/d/html/14636.html" rel="external">"Obsessive-compulsive disorder in adults: Psychotherapy"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial, 34 college students were randomly assigned to treatment with a four-session course of cognitive-behavioral treatment or a waiting list control group [<a href="#rid59">59</a>]. Skin picking severity measures (skin picking scale, skin picking impact scale, and self-control cognition questionnaire) decreased more in the treatment group compared with the no intervention group. Treatment effects were maintained at two months after the end of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another trial, 25 adults were randomly assigned to a habit reversal treatment (one-hour treatment session followed by two 30-minute booster sessions over the next three weeks) or a waiting list and were followed up for three months [<a href="#rid57">57</a>]. The number of skin picking episodes decreased significantly over time in the treatment group compared with the waiting list group. Benefits were maintained at three-month follow-up.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An internet-based self-help program of cognitive-behavioral therapy for the treatment of SPD was evaluated in a 12-week, randomized trial including 133 participants (93 percent female) [<a href="#rid60">60</a>]. Compared with the waiting list control group, participants in the intervention group showed substantial improvements in skin picking severity from baseline, as assessed by the Skin Picking Scale-Revised, and were generally satisfied with the intervention.</p><p></p><p class="headingAnchor" id="H3893206844"><span class="h2">Pharmacologic therapies</span></p><p class="headingAnchor" id="H7747794"><span class="h3">Antidepressants</span><span class="headingEndMark"> — </span>When pharmacotherapy is selected for the treatment of SPD, we suggest initial treatment with selective serotonin reuptake inhibitor (SSRI) antidepressants, which include <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a>, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a>, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>. SSRIs have been shown to be efficacious in the treatment of obsessive-compulsive disorder [<a href="#rid61">61</a>]. However, SSRIs for SPD have been evaluated only in a limited number of small clinical trials, some with significant dropout rates and wide confidence intervals, and their efficacy for SPD remains uncertain [<a href="#rid62">62-66</a>]. </p><p>A meta-analysis of two randomized trials and three uncontrolled studies found that SPD patients on SSRIs experienced improvement over time [<a href="#rid67">67</a>]. However, the analysis limited to the two randomized trials did not show any benefit of SSRIs compared with placebo. </p><p>SSRIs should generally be started at their minimal effective dose: <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> 20 mg, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a> 20 mg, <a class="drug drug_general" data-topicid="8874" href="/d/drug information/8874.html" rel="external">citalopram</a> 20 mg, <a class="drug drug_general" data-topicid="9046" href="/d/drug information/9046.html" rel="external">escitalopram</a> 10 mg, <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a> 25 to 50 mg, and <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a> 25 to 50 mg. The dose can be increased every week or every other week, as tolerated. The clinical response to the SSRI antidepressant is gradual. Patients showing no response at six to eight weeks may be switched to another class of antidepressants.</p><p>Common SSRI side effects include sexual dysfunction, drowsiness, weight gain, insomnia, anxiety, dizziness, headache, and dry mouth. When discontinuing an SSRI, a slow taper is advised due to withdrawal symptoms, such as nausea, diaphoresis, agitation, anxiety, dizziness, and sensory problems. (See  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Prescribing SSRIs'</a> and  <a class="medical medical_review" href="/d/html/14675.html" rel="external">"Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H7747801"><span class="h3">Antipsychotics</span><span class="headingEndMark"> — </span>Atypical antipsychotics, such as <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> or <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, may be helpful in selected patients with SPD, particularly in delusional patients. (See  <a class="medical medical_review" href="/d/html/15747.html" rel="external">"Treatment of delusional infestation"</a>.)</p><p><a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">Olanzapine</a> 2.5 to 5 mg per day and <a class="drug drug_general" data-topicid="10174" href="/d/drug information/10174.html" rel="external">paliperidone</a> 3 to 6 mg per day, either alone or with an antidepressant, have been shown to reduce SPD behaviors in case reports [<a href="#rid68">68-70</a>].</p><p class="headingAnchor" id="H1296099999"><span class="h3">Glutamate-modulating drugs</span></p><p class="headingAnchor" id="H1888300148"><span class="h4">N-acetylcysteine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> (an amino acid derivative that has glutamate-modulating properties) has been used alone or in combination with SSRI for the treatment of obsessive-compulsive disorders in adults and children with promising results [<a href="#rid71">71-74</a>]. (See  <a class="medical medical_review" href="/d/html/14629.html" rel="external">"Management of obsessive-compulsive disorder in adults"</a> and  <a class="medical medical_review" href="/d/html/90748.html" rel="external">"Obsessive-compulsive disorder in children and adolescents: Treatment overview", section on 'Glutamate modulators'</a>.)</p><p>Data from a few case series and single case reports suggest that <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a> reduced the symptom severity in patients with SPD [<a href="#rid75">75-77</a>]. The efficacy of N-acetylcysteine for the treatment of SPD has been evaluated in a randomized trial in which 66 participants with SPD received N-acetylcysteine at a dose of up to 3000 mg per day or placebo for 12 weeks [<a href="#rid78">78</a>]. The main outcome measures were changes in the modified Yale-Brown Obsessive-Compulsive Scale score and in the Clinical Global Impression severity scale score. At the end of the study, participants in the N-acetylcysteine group showed a significantly greater improvement in both scores compared with participants in the placebo group. The treatment was generally well tolerated. However, given the chronic nature of SPD, further studies are needed to evaluate the long-term efficacy and safety of N-acetylcysteine for the treatment of this disorder.</p><p class="headingAnchor" id="H3160331924"><span class="h4">Memantine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">Memantine</a> is an antagonist of the N-methyl-D-aspartate receptor that is activated by glutamate. Memantine is approved by the US Food and Drug Administration for the treatment of moderate to severe Alzheimer disease. (See  <a class="medical medical_review" href="/d/html/5073.html" rel="external">"Treatment of Alzheimer disease", section on 'Memantine'</a>.) </p><p>In a randomized trial, 100 patients with trichotillomania, SPD, or both were assigned to treatment with <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a> 10 mg/day for two weeks and then 20 mg/day for six weeks or placebo [<a href="#rid79">79</a>]. The rates of psychiatric comorbidities and current use of therapeutic doses of antidepressants were similar in the two groups. The primary outcome measure was change from baseline to week 8 in total symptom score on the modified National Institute of Mental Health Trichotillomania Symptom Severity Scale (range 0 to 20). At week 8, the average National Institute of Mental Health Trichotillomania Symptom Severity Scale score decrease from baseline was -6.98 in the memantine group versus -1.19 in the placebo group. Moreover, at week 8, more participants in the memantine group achieved a Clinical Global Impressions improvement scale score of "much or very much improved" than participants in the placebo group (60.5 versus 8.3 percent, respectively). Treatment was generally well tolerated. Adverse effects occurred with similar frequency in both groups and included fatigue/drowsiness, nausea, constipation, and dizziness.</p><p class="headingAnchor" id="H7747808"><span class="h3">Anxiolytics</span><span class="headingEndMark"> — </span>Anxiolytics may be used when the underlying cause of SPD is an anxiety disorder, although there are no specific studies of the use of anxiolytic drugs in the treatment of SPD. <a class="drug drug_general" data-topicid="9573" href="/d/drug information/9573.html" rel="external">Lorazepam</a> is a shorter-acting benzodiazepine that can be dosed at 0.5 to 1 mg four times daily, as needed, depending on the severity of symptoms [<a href="#rid80">80</a>]. Treatment duration should be short-term due to the risk of dependency. The most common side effect is sedation. If the anxiety disorder is chronic, <a class="drug drug_general" data-topicid="9172" href="/d/drug information/9172.html" rel="external">buspirone</a> at doses of 10 to 30 mg twice daily may be helpful. (See  <a class="medical medical_review" href="/d/html/101879.html" rel="external">"Generalized anxiety disorder in adults: Management"</a>.)</p><p class="headingAnchor" id="H2477019500"><span class="h2">Neuromodulation procedures</span><span class="headingEndMark"> — </span>Repetitive transcranial magnetic stimulation, a neuromodulation procedure used for the treatment of unipolar depression in adults who do not respond to standard treatment, was used in a small, preliminary, randomized study including 15 patients with SPD [<a href="#rid81">81</a>]. Treatment response, as assessed by the Yale-Brown Obsessive-Compulsive Scale Modified for Neurotic Excoriation, was achieved by five of eight patients in the active treatment group versus two of six in the sham group. Relapse occurred in one to three months after completing the study. (See  <a class="medical medical_review" href="/d/html/16519.html" rel="external">"Unipolar depression in adults: Overview of neuromodulation procedures", section on 'Repetitive transcranial magnetic stimulation'</a>.)</p><p class="headingAnchor" id="H2616244457"><span class="h2">Supplementary therapies</span><span class="headingEndMark"> — </span>There are very limited data on the use of alternative treatments for SPD (eg, yoga, aerobic exercise, hypnosis, acupuncture, and biofeedback) as possible adjuncts to standard treatments in SPD [<a href="#rid82">82</a>].</p><p class="headingAnchor" id="H59505419"><span class="h1">RELATED DISORDERS</span></p><p class="headingAnchor" id="H59505425"><span class="h2">Trichotillomania</span></p><p class="headingAnchor" id="H74463"><span class="h3">Definition and classification</span><span class="headingEndMark"> — </span>Trichotillomania (TTM), or hair pulling disorder, is a repetitive body-focused disorder frequently associated with skin picking [<a href="#rid83">83</a>]. TTM, previously classified as an impulse control disorder, is included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a separate diagnosis in the group of the obsessive-compulsive and related disorders, along with SPD and body dysmorphic disorder [<a href="#rid2">2</a>]. Whether SPD, TTM, and nail picking disorder are separate entities or different manifestations of the same disorder (pathologic grooming) remains unclear [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H69437123"><span class="h3">Etiology and pathogenesis</span><span class="headingEndMark"> — </span>The precise etiology of TTM is unknown. A twin study suggests that genetic factors may be important [<a href="#rid85">85</a>]. There is limited evidence that abnormalities in neurotransmitter systems (eg, serotonin, dopamine, norepinephrine, glutamate) may be involved in the pathogenesis of TTM. Neuroimaging studies have found increased resting cerebral glucose metabolic rates in TTM patients compared with healthy controls and an increase in gray matter density in several brain regions involved in affect regulation, motor habits, and top-down behavioral inhibition or white matter tract abnormalities [<a href="#rid86">86-88</a>].</p><p class="headingAnchor" id="H74469"><span class="h3">Epidemiology</span><span class="headingEndMark"> — </span>The exact prevalence of TTM in the general population is unknown. One study found a 0.6 percent lifetime prevalence of TTM among college students [<a href="#rid89">89</a>]. Another study found a 1 percent lifetime prevalence of TTM among 17-year-old teenagers [<a href="#rid90">90</a>]. The estimated lifetime prevalence ranges between 0.6 percent and 4 percent, with the highest incidence observed in childhood. However, estimates may change due to different diagnostic criteria used.</p><p class="headingAnchor" id="H74476"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>Patients with TTM may present with bald spots in various body sites, including the scalp, face, arms, legs, and pubic areas. However, the scalp is the most common pulling site in both children and adults  (<a class="graphic graphic_picture graphicRef102267 graphicRef67336" href="/d/graphic/102267.html" rel="external">picture 9A-B</a>), but eyelashes and eyebrows are often involved  (<a class="graphic graphic_picture graphicRef96906 graphicRef96905" href="/d/graphic/96906.html" rel="external">picture 10A-B</a>). The scalp typically shows diffuse or bizarre-shaped patches of alopecia  (<a class="graphic graphic_picture graphicRef96903" href="/d/graphic/96903.html" rel="external">picture 11</a>) [<a href="#rid91">91</a>]. The hair shafts are typically of different length due to different points of breakage or pulling at different times  (<a class="graphic graphic_picture graphicRef102267" href="/d/graphic/102267.html" rel="external">picture 9A</a>).</p><p>Additional behaviors associated with TTM include hair biting and hair ingestion (trichophagy). The latter can lead to the rare, serious complication of trichobezoar ("hair ball"). (See  <a class="medical medical_review" href="/d/html/2535.html" rel="external">"Gastric bezoars"</a>.)</p><p class="headingAnchor" id="H320557481"><span class="h3">Comorbidities</span><span class="headingEndMark"> — </span>Among patients with TTM, there is a high prevalence of a number of conditions from different DSM-4 groups, including tic disorders, alcohol dependence, mood disorders, anxiety disorders, impulse control disorders, and bulimia nervosa. In a study of 131 individuals with lifetime TTM (median age of onset 13 years), obsessive-compulsive disorder was present in 87 percent, mood disorder in 64 percent, generalized anxiety disorder in 52 percent, and SPD in 44 percent [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H74483"><span class="h3">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of TTM is based upon history, a clinic interview, and a number of diagnostic criteria defined in the DSM-5.</p><p class="headingAnchor" id="H7932840"><span class="h4">DSM-5 criteria</span><span class="headingEndMark"> — </span>The diagnostic criteria for TTM proposed in the DSM-5 are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Recurrent pulling out of one's hair, resulting in hair loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeated attempts to decrease or stop hair pulling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hair pulling causes significant distress and impairment in at least one important area of functioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hair pulling or hair loss is not attributable to another medical condition.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The hair pulling is not better explained by the symptoms of another mental disorder (eg, attempts to improve a perceived defect or flaw in appearance in body dysmorphic disorder).</p><p></p><p>Disease severity can be assessed by using several validated instruments, including:</p><p class="bulletIndent1"><span class="glyph">●</span>The Massachusetts General Hospital Hairpulling Scale [<a href="#rid92">92</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The Yale-Brown Obsessive-Compulsive Scale [<a href="#rid93">93</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The Psychiatric Institute Trichotillomania Scale [<a href="#rid94">94</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The Trichotillomania Scale for Children [<a href="#rid95">95</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>The Milwaukee Inventory for Styles of Trichotillomania-Child Version [<a href="#rid96">96</a>]</p><p></p><p class="headingAnchor" id="H7932852"><span class="h4">Other diagnostic tests</span><span class="headingEndMark"> — </span>A skin biopsy may be useful to confirm the diagnosis and exclude other types of hair loss. In TTM, histology shows a noninflammatory, nonscarring alopecia with morphologic changes of follicular damage (trichomalacia) secondary to the external insult, including distortion of the hair follicle anatomy and perifollicular and intrafollicular hemorrhage [<a href="#rid97">97</a>]. The number of hair follicles is normal, with an increased number of catagen/telogen hair follicles without significant inflammation.</p><p class="headingAnchor" id="H74699"><span class="h3">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of TTM includes:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea capitis</strong> – Tinea capitis is a common fungal infection of the scalp and hair that most commonly occurs in children. The most common manifestations are scaly patches with alopecia  (<a class="graphic graphic_picture graphicRef101858" href="/d/graphic/101858.html" rel="external">picture 12</a>) and patches of alopecia with black dots at follicular orifices that represent broken hairs  (<a class="graphic graphic_picture graphicRef86628" href="/d/graphic/86628.html" rel="external">picture 13</a>). Potassium hydroxide examination and fungal culture confirm the diagnosis. (See  <a class="medical medical_review" href="/d/html/99983.html" rel="external">"Tinea capitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alopecia areata</strong> – Alopecia areata is a chronic, relapsing disorder characterized by nonscarring hair loss. Patients typically present with smooth, circular, discrete areas of complete hair loss that develop over a period of a few weeks  (<a class="graphic graphic_picture graphicRef71583 graphicRef79908" href="/d/graphic/71583.html" rel="external">picture 14A-B</a>). (See  <a class="medical medical_review" href="/d/html/3320.html" rel="external">"Alopecia areata: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monilethrix</strong> – Monilethrix (MIM #158000) is an autosomal dominant disorder characterized by hair shaft abnormalities and hair fragility  (<a class="graphic graphic_picture graphicRef87479" href="/d/graphic/87479.html" rel="external">picture 15</a>). Microscopic examination of the hair shaft reveals elliptical nodes, resulting in a beaded appearance  (<a class="graphic graphic_picture graphicRef87480" href="/d/graphic/87480.html" rel="external">picture 16</a>). (See  <a class="medical medical_review" href="/d/html/15678.html" rel="external">"Evaluation and diagnosis of hair loss", section on 'Inherited and acquired structural hair disorders'</a>.)</p><p></p><p class="headingAnchor" id="H74706"><span class="h3">Treatment</span><span class="headingEndMark"> — </span>Psychiatric referral is appropriate for patients with TTM. For patients accepting mental health professional referral, we suggest cognitive-behavioral psychotherapy and, in particular, habit reversal therapy, rather than pharmacologic therapy. (See  <a class="medical medical_review" href="/d/html/96504.html" rel="external">"Body dysmorphic disorder: Choosing treatment and prognosis", section on 'Cognitive-behavioral therapy'</a>.)</p><p>The management of TTM in children requires strong clinician-patient and clinician-parent/caregiver relationships [<a href="#rid98">98</a>]. For children in whom a trigger can be identified (eg, birth of a new sibling, new school), brief counseling and parental/caregiver support and reassurance may be sufficient to reverse the habit [<a href="#rid99">99</a>].</p><p>The efficacy of behavioral therapy and pharmacotherapy for TTM has been evaluated in a small number of randomized trials and meta-analyses, as summarized below:</p><p class="bulletIndent1"><span class="glyph">●</span>The benefit of behavioral therapy was confirmed in a 2020 meta-analysis of 24 trials that included 857 participants [<a href="#rid100">100</a>]. This study demonstrated a large effect size for cognitive-behavioral therapy with habit reversal training components, compared with control treatments or no treatments, using the Massachusetts General Hospital Hairpulling Scale or the National Institute of Mental Health Trichotillomania Symptom Severity Scale (standardized mean difference [SMD] -1.66, 95% CI -2.31 to 1.02).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2021 Cochrane review of 12 small, randomized trials found insufficient evidence from meta-analysis to confirm or refute the efficacy of any agent or class of medication, including antipsychotics, <a class="drug drug_general" data-topicid="9317" href="/d/drug information/9317.html" rel="external">N-acetylcysteine</a>, <a class="drug drug_general" data-topicid="9679" href="/d/drug information/9679.html" rel="external">naltrexone</a>, selective serotonin reuptake inhibitors (SSRIs), and tricyclic antidepressants, for the treatment of TTM in adults, adolescents, and children [<a href="#rid101">101</a>]. Low-quality evidence from two small included trials indicated probable benefit (reduction of hair pulling symptoms) of <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and N-acetylcysteine treatment in adults [<a href="#rid102">102,103</a>]. A separate trial in children and adolescents did not find any beneficial effect of N-acetylcysteine compared with placebo [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2023 eight-week, randomized trial that included 100 patients with trichotillomania, SPD, or both showed that <a class="drug drug_general" data-topicid="10131" href="/d/drug information/10131.html" rel="external">memantine</a>, an antagonist of the N-methyl-D-aspartate, was more effective than placebo in reducing the total symptom score on the modified National Institute of Mental Health Trichotillomania Symptom Severity Scale from baseline (average reduction -6.98 versus -1.19, respectively) [<a href="#rid79">79</a>]. Moreover, more participants in the memantine group achieved a Clinical Global Impressions improvement scale score of "much or very much improved" than participants in the placebo group (60.5 versus 8.3 percent, respectively). (See <a class="local">'Memantine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A 2014 meta-analysis of 11 randomized trials examined the efficacy of SSRI and behavioral therapy for the treatment of TTM; the SMD of change in hair pulling severity was the outcome measure [<a href="#rid105">105</a>]. This meta-analysis found a large effect size for behavioral therapy compared with no interventions (SMD 1.56, 95% CI 0.99-2.14) and only a moderate effect size for SSRI compared with placebo (SMD 0.46, 95% CI 0.06-0.86).</p><p></p><p class="headingAnchor" id="H59505431"><span class="h2">Nail picking disorder</span><span class="headingEndMark"> — </span>Nail picking disorder, or onychotillomania, is an uncommon condition in the spectrum of obsessive-compulsive disorder characterized by recurrent picking or pulling of fingernails or toenails, leading to shortening or destruction of the nails [<a href="#rid106">106</a>]. Habit-tic disorder is a variant of onychotillomania. It typically presents with a midline furrow in the nail plate; absence of the cuticle; and erythema, edema, and scaling of the proximal and lateral nail folds and periungual area  (<a class="graphic graphic_picture graphicRef105564" href="/d/graphic/105564.html" rel="external">picture 17</a>). The abnormality results from repeated, self-inflicted nail matrix trauma due to conscious or unconscious manipulation of the cuticle. Some patients may develop longitudinal melanonychia secondary to nail manipulation [<a href="#rid107">107</a>].</p><p>Treatments that have been used for onychotillomania include occlusive dressings, cognitive-behavioral therapy, and SSRIs.</p><p class="headingAnchor" id="H102174782"><span class="h3">Associated syndromes</span><span class="headingEndMark"> — </span>Onychotillomania may be one aspect of the behavioral abnormalities seen in Lesch-Nyhan syndrome and Smith-Magenis syndrome [<a href="#rid108">108</a>]. Lesch-Nyhan syndrome is an X-linked disorder caused by defects in the enzyme hypoxanthine-guanine phosphoribosyltransferase 1, resulting in alterations in purine metabolism and accumulation of uric acid. Patients present with motor dysfunction, intellectual disability, and self-injurious behavior, including chewing the fingers and biting the lips [<a href="#rid109">109</a>]. Smith-Magenis syndrome is a rare, multisystemic disorder caused by the deletion of 17p11.2 [<a href="#rid110">110</a>]. The syndrome is characterized by brachycephaly, midface hypoplasia, prognathism, hoarse voice, speech delay, psychomotor and growth retardation, cutaneous features, and self-injurious behavior. (See  <a class="medical medical_review" href="/d/html/16648.html" rel="external">"Microdeletion syndromes (chromosomes 12 to 22)", section on '17p11.2 deletion syndrome (Smith-Magenis syndrome)'</a>.)</p><p class="headingAnchor" id="H59505437"><span class="h2">Pachydermodactyly</span><span class="headingEndMark"> — </span>Pachydermodactyly (PDD) is a rare, benign form of superficial digital fibromatosis characterized by symmetrical, periarticular soft tissue swelling of the proximal interphalangeal joints  (<a class="graphic graphic_picture graphicRef104666" href="/d/graphic/104666.html" rel="external">picture 18</a>) [<a href="#rid111">111</a>]. The disorder is caused by repetitive local trauma or compulsive habits of interlacing the fingers or rubbing the fingers and predominantly affects young males. PDD has been reported in patients with generalized anxiety disorders and obsessive-compulsive disorder [<a href="#rid112">112,113</a>].</p><p class="headingAnchor" id="H3445017908"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/129322.html" rel="external">"Society guideline links: Skin picking disorder"</a>.)</p><p class="headingAnchor" id="H15211858"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and classification</strong> – Skin picking disorder (SPD) is the repetitive manipulation of the skin, with or without instrumentation, resulting in visible tissue damage and impairment in social functioning. Patients with SPD may present with features of impulse control disorder, obsessive-compulsive disorder, or both  (<a class="graphic graphic_table graphicRef67010" href="/d/graphic/67010.html" rel="external">table 2</a>). SPD is included in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a separate diagnosis in the group of the obsessive-compulsive and related disorders. (See <a class="local">'Definition and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Psychiatric comorbidities </strong>–<strong> </strong>Multiple psychiatric comorbidities are associated with SPD, including depression, bipolar disorder, obsessive-compulsive disorder, alcohol abuse or dependence, and trichotillomania (TTM). (See <a class="local">'Comorbid conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>–<strong> </strong>SPD appears as excoriated, polymorphic lesions of variable size in all stages of evolution, localized most frequently on the face  (<a class="graphic graphic_picture graphicRef60854 graphicRef72635 graphicRef53693 graphicRef61686" href="/d/graphic/60854.html" rel="external">picture 1A-D</a>). (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>–<strong> </strong>The diagnosis of SPD is supported by a list of DSM-5 diagnostic criteria. SPD should be differentiated from the excoriations seen in subgroups of patients with primary pruritic skin conditions, chronic pruritus associated with systemic diseases, or other psychocutaneous diseases. (See <a class="local">'Patient evaluation and diagnosis'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Psychiatric referral </strong>– Psychiatric referral is appropriate for patients with SPD, although many patients will not accept it. Patients with SPD should either be comanaged by a mental health specialist and dermatologist or managed by a specialist who has experience in both psychiatric and dermatologic disorders. (See <a class="local">'General considerations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Behavioral therapies </strong>– For patients with SPD accepting mental health professional referral, we suggest cognitive-behavioral therapy or habit reversal therapy, rather than pharmacologic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Behavioral therapies'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic therapies </strong>– Pharmacotherapy may be appropriate for patients with SPD in the following scenarios (see <a class="local">'Pharmacologic therapies'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with severe SPD that is not responsive to behavioral therapy or interferes with daily functioning, we suggest a selective serotonin reuptake inhibitor (SSRI) antidepressant (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Evidence is limited, but we typically initiate treatment with <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a> 20 mg per day, titrating the dose up every two to four weeks as needed and tolerated. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In patients presenting with features of delusional disorder, antipsychotic medications may be indicated. Atypical antipsychotics, such as <a class="drug drug_general" data-topicid="9716" href="/d/drug information/9716.html" rel="external">olanzapine</a> and <a class="drug drug_general" data-topicid="9868" href="/d/drug information/9868.html" rel="external">risperidone</a>, are options, but their use has only been described in case reports. (See <a class="local">'Antidepressants'</a> above and <a class="local">'Antipsychotics'</a> above and  <a class="medical medical_review" href="/d/html/15747.html" rel="external">"Treatment of delusional infestation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment of skin lesions </strong>– Complications of SPD, including skin infection or disfigurement, may require medical, surgical, or cosmetic intervention. Topical and/or systemic antibiotics may be prescribed to treat secondarily infected excoriations or ulcerations. Semiocclusive dressings may be useful to limit further skin damage and promote healing. Potent topical  (<a class="graphic graphic_table graphicRef62402" href="/d/graphic/62402.html" rel="external">table 1</a>) or intralesional corticosteroids or narrowband ultraviolet B phototherapy are options for patients with skin lesions associated with intense pruritus. In patients with acne excoriée, aggressive treatment of the underlying acne should be initiated. (See <a class="local">'Treatment of skin lesions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disorders related to skin picking disorder</strong>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Trichotillomania</strong> – Trichotillomania (TTM), or hair pulling disorder, is a repetitive body-focused disorder frequently associated with skin picking and included in the DSM-5 as a separate diagnosis in the group of the obsessive-compulsive and related disorders. Patients with TTM present with bald spots in various body sites, including the scalp  (<a class="graphic graphic_picture graphicRef102267" href="/d/graphic/102267.html" rel="external">picture 9A</a>), face  (<a class="graphic graphic_picture graphicRef96905" href="/d/graphic/96905.html" rel="external">picture 10B</a>), arms, legs, and pubic areas. (See <a class="local">'Definition and classification'</a> above and <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2">The diagnosis of TTM is supported by a list of DSM-5 diagnostic criteria. A skin biopsy may be useful to confirm the diagnosis and exclude other causes of hair loss. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent2">Psychiatric referral is appropriate for patients with TTM. For patients with TTM accepting mental health professional referral, we suggest cognitive-behavioral therapy, rather than pharmacologic therapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Trichotillomania'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nail picking disorder</strong> – Nail picking disorder, or onychotillomania, is an uncommon condition in the spectrum of obsessive-compulsive disorder characterized by recurrent picking or pulling of fingernails or toenails, leading to shortening or destruction of the nail plates  (<a class="graphic graphic_picture graphicRef105564" href="/d/graphic/105564.html" rel="external">picture 17</a>). (See <a class="local">'Nail picking disorder'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pachydermodactyly</strong> – Pachydermodactyly is a rare, benign form of superficial digital fibromatosis characterized by symmetrical, periarticular soft tissue swelling of the proximal interphalangeal joints  (<a class="graphic graphic_picture graphicRef104666" href="/d/graphic/104666.html" rel="external">picture 18</a>) caused by repetitive local trauma or compulsive habits of interlacing the fingers or rubbing the fingers. (See <a class="local">'Pachydermodactyly'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Arnold LM, Auchenbach MB, McElroy SL. Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment. CNS Drugs 2001; 15:351.</a></li><li class="breakAll">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.</li><li><a class="nounderline abstract_t">Grant JE, Chamberlain SR. Prevalence of skin picking (excoriation) disorder. J Psychiatr Res 2020; 130:57.</a></li><li><a class="nounderline abstract_t">Griesemer RD. Emotionally triggered disease in a dermatologic practice. Psychiatr Ann 1978; 8:407.</a></li><li><a class="nounderline abstract_t">Gupta MA, Gupta AK, Haberman HF. The self-inflicted dermatoses: a critical review. Gen Hosp Psychiatry 1987; 9:45.</a></li><li><a class="nounderline abstract_t">Keuthen NJ, Koran LM, Aboujaoude E, et al. The prevalence of pathologic skin picking in US adults. Compr Psychiatry 2010; 51:183.</a></li><li><a class="nounderline abstract_t">Hayes SL, Storch EA, Berlanga L. Skin picking behaviors: An examination of the prevalence and severity in a community sample. J Anxiety Disord 2009; 23:314.</a></li><li><a class="nounderline abstract_t">Machado MO, Köhler CA, Stubbs B, et al. Skin picking disorder: prevalence, correlates, and associations with quality of life in a large sample. CNS Spectr 2018; 23:311.</a></li><li><a class="nounderline abstract_t">Keuthen NJ, Deckersbach T, Wilhelm S, et al. Repetitive skin-picking in a student population and comparison with a sample of self-injurious skin-pickers. Psychosomatics 2000; 41:210.</a></li><li><a class="nounderline abstract_t">Bohne A, Wilhelm S, Keuthen NJ, et al. Skin picking in German students. Prevalence, phenomenology, and associated characteristics. Behav Modif 2002; 26:320.</a></li><li><a class="nounderline abstract_t">Odlaug BL, Lust K, Schreiber LR, et al. Skin picking disorder in university students: health correlates and gender differences. Gen Hosp Psychiatry 2013; 35:168.</a></li><li><a class="nounderline abstract_t">Houghton DC, Alexander JR, Bauer CC, Woods DW. Body-focused repetitive behaviors: More prevalent than once thought? Psychiatry Res 2018; 270:389.</a></li><li><a class="nounderline abstract_t">Odlaug BL, Grant JE. Clinical characteristics and medical complications of pathologic skin picking. Gen Hosp Psychiatry 2008; 30:61.</a></li><li><a class="nounderline abstract_t">Arnold LM, McElroy SL, Mutasim DF, et al. Characteristics of 34 adults with psychogenic excoriation. J Clin Psychiatry 1998; 59:509.</a></li><li><a class="nounderline abstract_t">Grant JE, Chamberlain SR. Characteristics of 262 adults with skin picking disorder. Compr Psychiatry 2022; 117:152338.</a></li><li><a class="nounderline abstract_t">Ricketts EJ, Snorrason Í, Kircanski K, et al. A latent profile analysis of age of onset in pathological skin picking. Compr Psychiatry 2018; 87:46.</a></li><li><a class="nounderline abstract_t">Odlaug BL, Grant JE. Childhood-onset pathologic skin picking: clinical characteristics and psychiatric comorbidity. Compr Psychiatry 2007; 48:388.</a></li><li><a class="nounderline abstract_t">Odlaug BL, Hampshire A, Chamberlain SR, Grant JE. Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study. Br J Psychiatry 2016; 208:168.</a></li><li><a class="nounderline abstract_t">Grant JE, Odlaug BL, Hampshire A, et al. White matter abnormalities in skin picking disorder: a diffusion tensor imaging study. Neuropsychopharmacology 2013; 38:763.</a></li><li><a class="nounderline abstract_t">Wabnegger A, Schienle A. The Role of the Cerebellum in Skin-Picking Disorder. Cerebellum 2019; 18:91.</a></li><li><a class="nounderline abstract_t">Schienle A, Übel S, Wabnegger A. Visual symptom provocation in skin picking disorder: an fMRI study. Brain Imaging Behav 2018; 12:1504.</a></li><li><a class="nounderline abstract_t">Blum AW, Chamberlain SR, Harries MD, et al. Neuroanatomical Correlates of Impulsive Action in Excoriation (Skin-Picking) Disorder. J Neuropsychiatry Clin Neurosci 2018; 30:236.</a></li><li><a class="nounderline abstract_t">Neziroglu F, Rabinowitz D, Breytman A, Jacofsky M. Skin picking phenomenology and severity comparison. Prim Care Companion J Clin Psychiatry 2008; 10:306.</a></li><li><a class="nounderline abstract_t">Wilhelm S, Keuthen NJ, Deckersbach T, et al. Self-injurious skin picking: clinical characteristics and comorbidity. J Clin Psychiatry 1999; 60:454.</a></li><li><a class="nounderline abstract_t">Mutasim DF, Adams BB. The psychiatric profile of patients with psychogenic excoriation. J Am Acad Dermatol 2009; 61:611.</a></li><li><a class="nounderline abstract_t">Gerstenblith TA, Jaramillo-Huff A, Ruutiainen T, et al. Trichotillomania comorbidity in a sample enriched for familial obsessive-compulsive disorder. Compr Psychiatry 2019; 94:152123.</a></li><li class="breakAll">Obermeyer ME. Psychocutaneous Medicine, Charles C Thomas, 1995.</li><li><a class="nounderline abstract_t">Parent DJ, Krafft T, Noel JC, et al. Cutaneous Münchausen syndrome with presentation simulating pyoderma gangrenosum. J Am Acad Dermatol 1994; 31:1072.</a></li><li class="breakAll">Koblenzer CS. Psychocutaneous Disease, Grune and Stratton, 1987.</li><li><a class="nounderline abstract_t">Mackee GM. Neurotic excoriations. Arch Dermatol Syphilol 1920; 1:256.</a></li><li><a class="nounderline abstract_t">Cossidente A, Sarti MG. Psychiatric syndromes with dermatologic expression. Clin Dermatol 1984; 2:201.</a></li><li><a class="nounderline abstract_t">Koblenzer CS. Psychotropic drugs in dermatology. Curr Opinion Dermatol 1996; 3:214.</a></li><li><a class="nounderline abstract_t">Phillips KA, Taub SL. Skin picking as a symptom of body dysmorphic disorder. Psychopharmacol Bull 1995; 31:279.</a></li><li><a class="nounderline abstract_t">Jones G, Keuthen N, Greenberg E. Assessment and treatment of trichotillomania (hair pulling disorder) and excoriation (skin picking) disorder. Clin Dermatol 2018; 36:728.</a></li><li><a class="nounderline abstract_t">Keuthen NJ, Deckersbach T, Wilhelm S, et al. The Skin Picking Impact Scale (SPIS): scale development and psychometric analyses. Psychosomatics 2001; 42:397.</a></li><li><a class="nounderline abstract_t">Snorrason I, Olafsson RP, Flessner CA, et al. The Skin Picking Impact Scale: Factor structure, validity and development of a short version. Scand J Psychol 2013; 54:344.</a></li><li><a class="nounderline abstract_t">Walther MR, Flessner CA, Conelea CA, Woods DW. The Milwaukee Inventory for the Dimensions of Adult Skin Picking (MIDAS): initial development and psychometric properties. J Behav Ther Exp Psychiatry 2009; 40:127.</a></li><li><a class="nounderline abstract_t">Jafferany M. Psychodermatology: a guide to understanding common psychocutaneous disorders. Prim Care Companion J Clin Psychiatry 2007; 9:203.</a></li><li class="breakAll">Koo JY, Lee CS. General approach to evaluating psychodermatological disorders. In: Psychocutaneous Medicine, Koo JY, Lee CS (Eds), Dekker, 2003. p.1.</li><li><a class="nounderline abstract_t">Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381:320.</a></li><li><a class="nounderline abstract_t">Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol 2018; 32:1059.</a></li><li><a class="nounderline abstract_t">Moss C, Srinivas SM, Sarveswaran N, et al. Midface toddler excoriation syndrome (MiTES) can be caused by autosomal recessive biallelic mutations in a gene for congenital insensitivity to pain, PRDM12. Br J Dermatol 2018; 179:1135.</a></li><li><a class="nounderline abstract_t">Inamadar AC, Vinay K, Olabi B, et al. Extending the phenotype of midface toddler excoriation syndrome (MiTES): Five new cases in three families with PR domain containing protein 12 (PRDM12) mutations. J Am Acad Dermatol 2019; 81:1415.</a></li><li><a class="nounderline abstract_t">Srinivas SM, Gowda VK, Owen CM, et al. Mid-face toddler excoriation syndrome (MiTES): a new paediatric diagnosis. Clin Exp Dermatol 2017; 42:68.</a></li><li class="breakAll">Graves MW. Pruritus. In: Rook's Textbook of Dermatology, 8th ed, Burns T, Breathnach S, Cox N, Griffiths C (Eds), Wiley-Blackwell, 2010. Vol 1.</li><li><a class="nounderline abstract_t">Kuhn H, Mennella C, Magid M, et al. Psychocutaneous disease: Clinical perspectives. J Am Acad Dermatol 2017; 76:779.</a></li><li><a class="nounderline abstract_t">Lavery MJ, Stull C, McCaw I, Anolik RB. Dermatitis artefacta. Clin Dermatol 2018; 36:719.</a></li><li class="breakAll">Chandran V, Kurien G. Dermatitis artefacta. In: StatPearls, StatPearls Publishing, Treasure Island (FL) 2019.</li><li class="breakAll">Hurwitz Clinical Pediatric Dermatology, 3rd ed, Paller AS, Mancini AJ (Eds), Elsevier Inc, 2006. p.678.</li><li class="breakAll">Millard LG, Millard J. Psychocutaneous disorders. In: Rook's Textbook of Dermatology, 8th ed, Burns T, Breathnach S, Cox N, Griffiths C (Eds), Wiley-Blackwell, 2010. Vol 4.</li><li><a class="nounderline abstract_t">Phillips KA, Dufresne RG. Body dysmorphic disorder. A guide for dermatologists and cosmetic surgeons. Am J Clin Dermatol 2000; 1:235.</a></li><li><a class="nounderline abstract_t">Lochner C, Roos A, Stein DJ. Excoriation (skin-picking) disorder: a systematic review of treatment options. Neuropsychiatr Dis Treat 2017; 13:1867.</a></li><li><a class="nounderline abstract_t">Koo JY, Ng TC. Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications. Clin Dermatol 2002; 20:582.</a></li><li><a class="nounderline abstract_t">Ozden MG, Aydin F, Sentürk N, et al. Narrow-band ultraviolet B as a potential alternative treatment for resistant psychogenic excoriation: an open-label study. Photodermatol Photoimmunol Photomed 2010; 26:162.</a></li><li><a class="nounderline abstract_t">Bowes LE, Alster TS. Treatment of facial scarring and ulceration resulting from acne excoriée with 585-nm pulsed dye laser irradiation and cognitive psychotherapy. Dermatol Surg 2004; 30:934.</a></li><li><a class="nounderline abstract_t">Deckersbach T, Wilhelm S, Keuthen NJ, et al. Cognitive-behavior therapy for self-injurious skin picking. A case series. Behav Modif 2002; 26:361.</a></li><li><a class="nounderline abstract_t">Teng EJ, Woods DW, Twohig MP. Habit reversal as a treatment for chronic skin picking: a pilot investigation. Behav Modif 2006; 30:411.</a></li><li><a class="nounderline abstract_t">Flessner CA, Busch AM, Heideman PW, Woods DW. Acceptance-enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing. Behav Modif 2008; 32:579.</a></li><li><a class="nounderline abstract_t">Schuck K, Keijsers GP, Rinck M. The effects of brief cognitive-behaviour therapy for pathological skin picking: A randomized comparison to wait-list control. Behav Res Ther 2011; 49:11.</a></li><li><a class="nounderline abstract_t">Gallinat C, Moessner M, Haenssle HA, et al. An Internet-Based Self-Help Intervention for Skin Picking (SaveMySkin): Pilot Randomized Controlled Trial. J Med Internet Res 2019; 21:e15011.</a></li><li><a class="nounderline abstract_t">Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev 2008; :CD001765.</a></li><li><a class="nounderline abstract_t">Simeon D, Stein DJ, Gross S, et al. A double-blind trial of fluoxetine in pathologic skin picking. J Clin Psychiatry 1997; 58:341.</a></li><li><a class="nounderline abstract_t">Bloch MR, Elliott M, Thompson H, Koran LM. Fluoxetine in pathologic skin-picking: open-label and double-blind results. Psychosomatics 2001; 42:314.</a></li><li><a class="nounderline abstract_t">Arbabi M, Farnia V, Balighi K, et al. Efficacy of citalopram in treatment of pathological skin picking, a randomized double blind placebo controlled trial. Acta Medica Iranica 2008; 46:367.</a></li><li><a class="nounderline abstract_t">Keuthen NJ, Jameson M, Loh R, et al. Open-label escitalopram treatment for pathological skin picking. Int Clin Psychopharmacol 2007; 22:268.</a></li><li><a class="nounderline abstract_t">Kalivas J, Kalivas L, Gilman D, Hayden CT. Sertraline in the treatment of neurotic excoriations and related disorders. Arch Dermatol 1996; 132:589.</a></li><li><a class="nounderline abstract_t">Schumer MC, Bartley CA, Bloch MH. Systematic Review of Pharmacological and Behavioral Treatments for Skin Picking Disorder. J Clin Psychopharmacol 2016; 36:147.</a></li><li><a class="nounderline abstract_t">Gupta MA, Gupta AK. Olanzapine is effective in the management of some self-induced dermatoses: three case reports. Cutis 2000; 66:143.</a></li><li><a class="nounderline abstract_t">Christensen RC. Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking. Can J Psychiatry 2004; 49:788.</a></li><li><a class="nounderline abstract_t">Spiegel DR, Finklea L. The recognition and treatment of pathological skin picking: a potential neurobiological underpinning of the efficacy of pharmacotherapy in impulse control disorders. Psychiatry (Edgmont) 2009; 6:38.</a></li><li><a class="nounderline abstract_t">Oliver G, Dean O, Camfield D, et al. N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci 2015; 13:12.</a></li><li><a class="nounderline abstract_t">Paydary K, Akamaloo A, Ahmadipour A, et al. N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2016; 41:214.</a></li><li><a class="nounderline abstract_t">Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neurosci Biobehav Rev 2015; 55:294.</a></li><li><a class="nounderline abstract_t">Nwankwo CO, Jafferany M. N-Acetylcysteine in psychodermatological disorders. Dermatol Ther 2019; 32:e13073.</a></li><li><a class="nounderline abstract_t">Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A 2014; 164A:421.</a></li><li><a class="nounderline abstract_t">Odlaug BL, Grant JE. N-acetyl cysteine in the treatment of grooming disorders. J Clin Psychopharmacol 2007; 27:227.</a></li><li><a class="nounderline abstract_t">Hwang AS, Campbell EH, Sartori-Valinotti JC. Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study. J Am Acad Dermatol 2022; 87:148.</a></li><li><a class="nounderline abstract_t">Grant JE, Chamberlain SR, Redden SA, et al. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2016; 73:490.</a></li><li><a class="nounderline abstract_t">Grant JE, Chesivoir E, Valle S, et al. Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder. Am J Psychiatry 2023; 180:348.</a></li><li class="breakAll">Lee CS, Koo JY. Psychotropic agents. In: Comprehensive Dermatologic Drug Therapy, 2nd ed, Wolverton SE (Ed), Elsevier, 2007. p.402.</li><li><a class="nounderline abstract_t">Aydin EP, Kenar JG, Altunay İK, et al. Repetitive Transcranial Magnetic Stimulation in the Treatment of Skin Picking Disorder: An Exploratory Trial. J ECT 2020; 36:60.</a></li><li><a class="nounderline abstract_t">Torales J, Barrios I, Villalba J. Alternative Therapies for Excoriation (Skin Picking) Disorder: A Brief Update. Adv Mind Body Med 2017; 31:10.</a></li><li><a class="nounderline abstract_t">Woods DW, Houghton DC. Diagnosis, evaluation, and management of trichotillomania. Psychiatr Clin North Am 2014; 37:301.</a></li><li><a class="nounderline abstract_t">Maraz A, Hende B, Urbán R, Demetrovics Z. Pathological grooming: Evidence for a single factor behind trichotillomania, skin picking and nail biting. PLoS One 2017; 12:e0183806.</a></li><li><a class="nounderline abstract_t">Novak CE, Keuthen NJ, Stewart SE, Pauls DL. A twin concordance study of trichotillomania. Am J Med Genet B Neuropsychiatr Genet 2009; 150B:944.</a></li><li><a class="nounderline abstract_t">Swedo SE, Rapoport JL, Leonard HL, et al. Regional cerebral glucose metabolism of women with trichotillomania. Arch Gen Psychiatry 1991; 48:828.</a></li><li><a class="nounderline abstract_t">Chamberlain SR, Menzies LA, Fineberg NA, et al. Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study. Br J Psychiatry 2008; 193:216.</a></li><li><a class="nounderline abstract_t">Roos A, Grant JE, Fouche JP, et al. A comparison of brain volume and cortical thickness in excoriation (skin picking) disorder and trichotillomania (hair pulling disorder) in women. Behav Brain Res 2015; 279:255.</a></li><li><a class="nounderline abstract_t">Christenson GA, Pyle RL, Mitchell JE. Estimated lifetime prevalence of trichotillomania in college students. J Clin Psychiatry 1991; 52:415.</a></li><li><a class="nounderline abstract_t">King RA, Zohar AH, Ratzoni G, et al. An epidemiological study of trichotillomania in Israeli adolescents. J Am Acad Child Adolesc Psychiatry 1995; 34:1212.</a></li><li><a class="nounderline abstract_t">Harrison JP, Franklin ME. Pediatric trichotillomania. Curr Psychiatry Rep 2012; 14:188.</a></li><li><a class="nounderline abstract_t">O'Sullivan RL, Keuthen NJ, Hayday CF, et al. The Massachusetts General Hospital (MGH) Hairpulling Scale: 2. reliability and validity. Psychother Psychosom 1995; 64:146.</a></li><li><a class="nounderline abstract_t">Stanley MA, Prather RC, Wagner AL, et al. Can the Yale-Brown Obsessive Compulsive Scale be used to assess trichotillomania? A preliminary report. Behav Res Ther 1993; 31:171.</a></li><li><a class="nounderline abstract_t">Winchel RM, Jones JS, Molcho A, et al. The Psychiatric Institute Trichotillomania Scale (PITS). Psychopharmacol Bull 1992; 28:463.</a></li><li><a class="nounderline abstract_t">Tolin DF, Diefenbach GJ, Flessner CA, et al. The trichotillomania scale for children: development and validation. Child Psychiatry Hum Dev 2008; 39:331.</a></li><li><a class="nounderline abstract_t">Flessner CA, Woods DW, Franklin ME, et al. The Milwaukee Inventory for Styles of Trichotillomania-Child Version (MIST-C): initial development and psychometric properties. Behav Modif 2007; 31:896.</a></li><li><a class="nounderline abstract_t">Stefanato CM. Histopathology of alopecia: a clinicopathological approach to diagnosis. Histopathology 2010; 56:24.</a></li><li><a class="nounderline abstract_t">Henkel ED, Jaquez SD, Diaz LZ. Pediatric trichotillomania: Review of management. Pediatr Dermatol 2019; 36:803.</a></li><li><a class="nounderline abstract_t">Tay YK, Levy ML, Metry DW. Trichotillomania in childhood: case series and review. Pediatrics 2004; 113:e494.</a></li><li><a class="nounderline abstract_t">Farhat LC, Olfson E, Nasir M, et al. Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta-analysis. Depress Anxiety 2020; 37:715.</a></li><li><a class="nounderline abstract_t">Hoffman J, Williams T, Rothbart R, et al. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev 2021; 9:CD007662.</a></li><li><a class="nounderline abstract_t">Grant JE, Odlaug BL, Kim SW. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2009; 66:756.</a></li><li><a class="nounderline abstract_t">Van Ameringen M, Mancini C, Patterson B, et al. A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania. J Clin Psychiatry 2010; 71:1336.</a></li><li><a class="nounderline abstract_t">Bloch MH, Panza KE, Grant JE, et al. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry 2013; 52:231.</a></li><li><a class="nounderline abstract_t">McGuire JF, Ung D, Selles RR, et al. Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors. J Psychiatr Res 2014; 58:76.</a></li><li><a class="nounderline abstract_t">Pacan P, Grzesiak M, Reich A, et al. Onychophagia and onychotillomania: prevalence, clinical picture and comorbidities. Acta Derm Venereol 2014; 94:67.</a></li><li><a class="nounderline abstract_t">Baran R. Nail biting and picking as a possible cause of longitudinal melanonychia. A study of 6 cases. Dermatologica 1990; 181:126.</a></li><li><a class="nounderline abstract_t">Reese JM, Hudacek KD, Rubin AI. Onychotillomania: clinicopathologic correlations. J Cutan Pathol 2013; 40:419.</a></li><li><a class="nounderline abstract_t">Torres RJ, Puig JG, Jinnah HA. Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants. Curr Rheumatol Rep 2012; 14:189.</a></li><li><a class="nounderline abstract_t">Elsea SH, Girirajan S. Smith-Magenis syndrome. Eur J Hum Genet 2008; 16:412.</a></li><li><a class="nounderline abstract_t">Dallos T, Oppl B, Kovács L, Zwerina J. Pachydermodactyly: a review. Curr Rheumatol Rep 2014; 16:442.</a></li><li><a class="nounderline abstract_t">Cabanillas M, Monteagudo B, León-Muíños E, Suárez-Amor O. Pachydermodactyly in a young girl: cutaneous manifestation of a psychiatric disorder? Pediatr Dermatol 2010; 27:306.</a></li><li><a class="nounderline abstract_t">Beltraminelli H, Itin P. Pachydermodactyly--just a sign of emotional distress. Eur J Dermatol 2009; 19:5.</a></li></ol></div><div id="topicVersionRevision">Topic 13698 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475941" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11475941" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Psychogenic excoriation. Clinical features, proposed diagnostic criteria, epidemiology and approaches to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32781374" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence of skin picking (excoriation) disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Emotionally triggered disease in a dermatologic practice</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3817460" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The self-inflicted dermatoses: a critical review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20152300" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The prevalence of pathologic skin picking in US adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19223150" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Skin picking behaviors: An examination of the prevalence and severity in a community sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29730999" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Skin picking disorder: prevalence, correlates, and associations with quality of life in a large sample.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10849452" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Repetitive skin-picking in a student population and comparison with a sample of self-injurious skin-pickers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12080904" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Skin picking in German students. Prevalence, phenomenology, and associated characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23123103" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Skin picking disorder in university students: health correlates and gender differences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30300869" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Body-focused repetitive behaviors: More prevalent than once thought?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18164942" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical characteristics and medical complications of pathologic skin picking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9818631" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Characteristics of 34 adults with psychogenic excoriation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843137" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Characteristics of 262 adults with skin picking disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30199665" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A latent profile analysis of age of onset in pathological skin picking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560962" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Childhood-onset pathologic skin picking: clinical characteristics and psychiatric comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26159604" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Abnormal brain activation in excoriation (skin-picking) disorder: evidence from an executive planning fMRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23303052" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : White matter abnormalities in skin picking disorder: a diffusion tensor imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29934941" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : The Role of the Cerebellum in Skin-Picking Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29305750" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Visual symptom provocation in skin picking disorder: an fMRI study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29685064" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuroanatomical Correlates of Impulsive Action in Excoriation (Skin-Picking) Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18787665" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Skin picking phenomenology and severity comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10453800" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Self-injurious skin picking: clinical characteristics and comorbidity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577820" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The psychiatric profile of patients with psychogenic excoriation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31518848" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Trichotillomania comorbidity in a sample enriched for familial obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31518848" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Trichotillomania comorbidity in a sample enriched for familial obsessive-compulsive disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962767" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cutaneous Münchausen syndrome with presentation simulating pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7962767" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Cutaneous Münchausen syndrome with presentation simulating pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neurotic excoriations</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6545773" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Psychiatric syndromes with dermatologic expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Psychotropic drugs in dermatology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7491380" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Skin picking as a symptom of body dysmorphic disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446196" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Assessment and treatment of trichotillomania (hair pulling disorder) and excoriation (skin picking) disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11739906" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The Skin Picking Impact Scale (SPIS): scale development and psychometric analyses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23682651" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The Skin Picking Impact Scale: Factor structure, validity and development of a short version.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725154" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The Milwaukee Inventory for the Dimensions of Adult Skin Picking (MIDAS): initial development and psychometric properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632653" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Psychodermatology: a guide to understanding common psychocutaneous disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632653" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Psychodermatology: a guide to understanding common psychocutaneous disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23237497" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Pemphigoid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28857299" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29949203" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Midface toddler excoriation syndrome (MiTES) can be caused by autosomal recessive biallelic mutations in a gene for congenital insensitivity to pain, PRDM12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31128170" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Extending the phenotype of midface toddler excoriation syndrome (MiTES): Five new cases in three families with PR domain containing protein 12 (PRDM12) mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28028858" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Mid-face toddler excoriation syndrome (MiTES): a new paediatric diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28028858" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Mid-face toddler excoriation syndrome (MiTES): a new paediatric diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28411771" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Psychocutaneous disease: Clinical perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446194" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Dermatitis artefacta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446194" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Dermatitis artefacta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446194" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Dermatitis artefacta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30446194" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Dermatitis artefacta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11702368" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Body dysmorphic disorder. A guide for dermatologists and cosmetic surgeons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28761349" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Excoriation (skin-picking) disorder: a systematic review of treatment options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12435529" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Psychotropic and neurotropic agents in dermatology: unapproved uses, dosages, or indications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584258" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Narrow-band ultraviolet B as a potential alternative treatment for resistant psychogenic excoriation: an open-label study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15171775" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Treatment of facial scarring and ulceration resulting from acne excoriée with 585-nm pulsed dye laser irradiation and cognitive psychotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12080906" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cognitive-behavior therapy for self-injurious skin picking. A case series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16723422" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Habit reversal as a treatment for chronic skin picking: a pilot investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18334614" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Acceptance-enhanced behavior therapy (AEBT) for trichotillomania and chronic skin picking: exploring the effects of component sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20934685" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The effects of brief cognitive-behaviour therapy for pathological skin picking: A randomized comparison to wait-list control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31586368" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : An Internet-Based Self-Help Intervention for Skin Picking (SaveMySkin): Pilot Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18253995" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9515971" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A double-blind trial of fluoxetine in pathologic skin picking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11496020" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Fluoxetine in pathologic skin-picking: open-label and double-blind results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Efficacy of citalopram in treatment of pathological skin picking, a randomized double blind placebo controlled trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17690595" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Open-label escitalopram treatment for pathological skin picking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8624163" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Sertraline in the treatment of neurotic excoriations and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26872117" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Systematic Review of Pharmacological and Behavioral Treatments for Skin Picking Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10955197" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Olanzapine is effective in the management of some self-induced dermatoses: three case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15633864" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Olanzapine augmentation of fluoxetine in the treatment of pathological skin picking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19724747" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The recognition and treatment of pathological skin picking: a potential neurobiological underpinning of the efficacy of pharmacotherapy in impulse control disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25912534" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26931055" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : N-acetylcysteine augmentation therapy for moderate-to-severe obsessive-compulsive disorder: randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25957927" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31444827" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : N-Acetylcysteine in psychodermatological disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24311388" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17414258" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : N-acetyl cysteine in the treatment of grooming disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224772" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Evidence of N-acetylcysteine efficacy for skin picking disorder: A retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27007062" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36856701" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36856701" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31232909" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Repetitive Transcranial Magnetic Stimulation in the Treatment of Skin Picking Disorder: An Exploratory Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28183072" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Alternative Therapies for Excoriation (Skin Picking) Disorder: A Brief Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25150564" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Diagnosis, evaluation, and management of trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28902896" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Pathological grooming: Evidence for a single factor behind trichotillomania, skin picking and nail biting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19199280" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A twin concordance study of trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929773" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Regional cerebral glucose metabolism of women with trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18757980" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Grey matter abnormalities in trichotillomania: morphometric magnetic resonance imaging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25435313" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : A comparison of brain volume and cortical thickness in excoriation (skin picking) disorder and trichotillomania (hair pulling disorder) in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1938977" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Estimated lifetime prevalence of trichotillomania in college students.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7559316" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : An epidemiological study of trichotillomania in Israeli adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22437627" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pediatric trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8657845" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The Massachusetts General Hospital (MGH) Hairpulling Scale: 2. reliability and validity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8442741" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Can the Yale-Brown Obsessive Compulsive Scale be used to assess trichotillomania? A preliminary report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1296224" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Psychiatric Institute Trichotillomania Scale (PITS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18183484" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The trichotillomania scale for children: development and validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932243" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : The Milwaukee Inventory for Styles of Trichotillomania-Child Version (MIST-C): initial development and psychometric properties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055903" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Histopathology of alopecia: a clinicopathological approach to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31588617" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Pediatric trichotillomania: Review of management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15121993" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Trichotillomania in childhood: case series and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32390221" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Pharmacological and behavioral treatment for trichotillomania: An updated systematic review with meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34582562" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pharmacotherapy for trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19581567" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20441724" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A randomized, double-blind, placebo-controlled trial of olanzapine in the treatment of trichotillomania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23452680" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25108618" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Treating trichotillomania: a meta-analysis of treatment effects and moderators for behavior therapy and serotonin reuptake inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23756561" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Onychophagia and onychotillomania: prevalence, clinical picture and comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2242780" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Nail biting and picking as a possible cause of longitudinal melanonychia. A study of 6 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398617" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Onychotillomania: clinicopathologic correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22198833" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Update on the phenotypic spectrum of Lesch-Nyhan disease and its attenuated variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18231123" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Smith-Magenis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25173950" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Pachydermodactyly: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20609157" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Pachydermodactyly in a young girl: cutaneous manifestation of a psychiatric disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19059823" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Pachydermodactyly--just a sign of emotional distress.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
